Find Ombitasvir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF DossiersDRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Finished Drug Prices

NA

3 RELATED EXCIPIENT COMPANIES

7EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1258226-87-7, Abt-267, Ombitasvir(abt-267), Abt267, Chebi:85183, Abt 267
Molecular Formula
C50H67N7O8
Molecular Weight
894.1  g/mol
InChI Key
PIDFDZJZLOTZTM-KHVQSSSXSA-N
FDA UNII
2302768XJ8

Ombitasvir
Ombitasvir is an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Upon oral administration and after intracellular uptake, ombitasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).
Ombitasvir is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ombitasvir is as an UGT1A1 Inhibitor.
1 2D Structure

Ombitasvir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
2.1.2 InChI
InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
2.1.3 InChI Key
PIDFDZJZLOTZTM-KHVQSSSXSA-N
2.1.4 Canonical SMILES
CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
2.1.5 Isomeric SMILES
CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
2.2 Other Identifiers
2.2.1 UNII
2302768XJ8
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Abt-267

2. Abt267

3. N,n'-(((2s,5s)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)bis(4,1-phenyleneiminocarbonyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-c,c'-dimethyl Ester Carbamic Acid

2.3.2 Depositor-Supplied Synonyms

1. 1258226-87-7

2. Abt-267

3. Ombitasvir(abt-267)

4. Abt267

5. Chebi:85183

6. Abt 267

7. Ombitasvir (usan)

8. Ombitasvir [usan]

9. 2302768xj8

10. Carbamic Acid, N,n'-(((2s,5s)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)bis(4,1-phenyleneiminocarbonyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,c'-dimethyl Ester

11. L-prolinamide, 2,2'-[[(2s,5s)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[n-(methoxycarbonyl)-l-valyl-

12. L-prolinamide,2,2'-(((2s,5s)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)di-4,1-phenylene)bis(n-(methoxycarbonyl)-l-valyl-

13. Dimethyl ([(2s,5s)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2s)pyrrolidine-2,1-diyl[(2s)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate

14. Methyl N-[(2s)-1-[(2s)-2-[[4-[(2s,5s)-1-(4-tert-butylphenyl)-5-[4-[[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

15. Ombitasvir [inn]

16. Ombitasvir [usan:inn]

17. Unii-2302768xj8

18. Ombitasvir [mi]

19. Ombitasvir [vandf]

20. Ombitasvir [who-dd]

21. Schembl8542284

22. Chembl3127326

23. Ombitasvir [orange Book]

24. Gtpl11272

25. Amy6935

26. Dtxsid201027920

27. Ex-a5846

28. Viekirax Component Ombitasvir

29. Bdbm50453112

30. S5403

31. Zinc150601177

32. Ccg-270561

33. Cs-5330

34. Db09296

35. Ombitasvir Component Of Viekirax

36. Abt-267;abt267;abt 267

37. Compound 38 [pmid: 24400777]

38. Ncgc00510316-01

39. Ncgc00510316-02

40. Hy-13997

41. C72037

42. D10576

43. Technivie (ombitasvir + Paritaprevir + Ritonavir)

44. Q19598175

45. Methyl ((s)-1-((s)-2-((4-((2s,5s)-1-(4-(tert-butyl)phenyl)-5-(4-((s)-1-((methoxycarbonyl)-l-valyl)pyrrolidine-2-carboxamido)phenyl)pyrrolidin-2-yl)phenyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate

46. Methyl N-[(1s)-1-[(2s)-2-[[4-[(2s,5s)-1-(4-tert-butylphenyl)-5-[4-[[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate

2.4 Create Date
2012-01-23
3 Chemical and Physical Properties
Molecular Weight 894.1 g/mol
Molecular Formula C50H67N7O8
XLogP37.9
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count9
Rotatable Bond Count16
Exact Mass893.50511212 g/mol
Monoisotopic Mass893.50511212 g/mol
Topological Polar Surface Area179 Ų
Heavy Atom Count65
Formal Charge0
Complexity1540
Isotope Atom Count0
Defined Atom Stereocenter Count6
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

When used in combination with [DB09297] and [DB00503] (as the fixed dose product Technivie), Ombitasvir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis. When used in combination with [DB09297], [DB00503], and [DB09183] (as the fixed dose product Viekira Pak), Ombitasvir is indicated for the treatment of HCV genotype 1b and ,when combined with [DB00811], for the treatment of HCV genotype 1a


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Ombitasvir is classified as a direct acting antiviral and acts against HCV to inhibit viral replication.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
OMBITASVIR
5.2.2 FDA UNII
2302768XJ8
5.2.3 Pharmacological Classes
Mechanisms of Action [MoA] - UGT1A1 Inhibitors
5.3 Absorption, Distribution and Excretion

Absorption

Ombitasvir reaches peak plasma concentration 5 hours after administration. It has an absolute bioavailability of 48%. Taking ombitasvir with high or normal fat meals increases exposure by 1.76 or 1.82 fold respectively.


Route of Elimination

Ombitasvir is mainly excreted in the feces (90.2%) with very little excreted in the urine (1.91%). 87.8% and 0.03% of the dose excreted in the feces and urine respectively is present as the parent compound.


Volume of Distribution

Ombitasvir has a volume of distribution at steady state of 173 liters.


Clearance

Clearance of Ombitasvir has not been determined.


5.4 Metabolism/Metabolites

Ombitasvir is mainly metabolized by amide hydrolysis followed by CYP2C8-mediated oxidative metabolism.


5.5 Biological Half-Life

Ombitasvir has a half life of elimination of 21-25 hours


5.6 Mechanism of Action

Ombitasvir is an inhibitor of the HCV non-structural protein 5A. While the precise role of this protein is unknown, it is essential to viral replication and virion assembly. Potential modes of action of NS5A inhibitors like Elbasvir include blocking signaling interactions, redistribution of NS5A from the endoplasmic reticulum to the surface of lipid droplets, and modification of the HCV replication complex.


DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - 12.5MG;75MG;50MG **Fed...DOSAGE - TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 207931

read-more

DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 2...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 208624

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Emulsifying Agents

read-more
read-more

Solubilizers

read-more
read-more

Topical

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty